Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07588139 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
A Phase 1 study, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07588139 is a Phase 1 study that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 24 participants.
The verdict
NCT07588139, a Phase 1 study, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the interstitial concentrations using the open-flow microperfusion device and plasma pharmacokinetics following multiple doses of povorcitinib or topical ruxolitinib cream in healthy adult participants.
Interventions
- DRUG Ruxolitinib
- DRUG Povorcitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-05-18 |
| Est. Completion | 2026-09-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07588139
The ClinicalTrials.gov registry entry for NCT07588139 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT07588139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07588139 about?
NCT07588139 is a clinical study titled "A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants". The purpose of this study is to evaluate the interstitial concentrations using the open-flow microperfusion device and plasma pharmacokinetics following multiple doses of povorcitinib or topical ruxolitinib cream in healthy adult participants.
What is the current status of trial NCT07588139?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-05-18. Estimated completion is 2026-09-19.
What interventions are being tested in trial NCT07588139?
The interventions under investigation include: Ruxolitinib (DRUG), Povorcitinib (DRUG).
Who is sponsoring clinical trial NCT07588139?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.